NR4A1 and triple-negative breast carcinoma: In the test cohort, there were 341 patients with hormone receptor (HoR)+ human epidermal growth factor receptor 2 (HER2)-, 34 with HER2+, and 43 with triple-negative breast cancer (TNBC) in the CNAB-low group, and 169 with HoR+HER2−, 58 with HER2+, and 68 with TNBC in the CNAB-high group.